Hepatitis E virus infection prevalence among men who have sex with men involved in a hepatitis A virus outbreak in Italy.


Journal

Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479

Informations de publication

Date de publication:
11 2019
Historique:
received: 05 09 2019
accepted: 23 09 2019
entrez: 18 12 2019
pubmed: 18 12 2019
medline: 8 5 2020
Statut: ppublish

Résumé

The routes of hepatitis E virus (HEV) transmission have still not been fully clarified. Here, we evaluated the possibility of sexual transmission of HEV, which remains a highly disputed issue. Hepatitis E virus sexual transmission risk was assessed by comparing the prevalence of HEV infection in a sample of 196 Italian men who have sex with men (MSM) involved in a multi-country hepatitis A virus (HAV) outbreak, and in 3,912 Italian male blood donors selected from the same regions and provinces as the MSM. Selection of study of participants was motivated by the fact that HEV prevalence among Italian blood donors has been found to vary enormously between different geographical areas. Anti-HEV IgG prevalence was 14.8% and 5.6% in blood donors and MSM, respectively. Adjusted anti-HEV IgG prevalence was significantly lower in MSM than in blood donors (odds ratio [OR], 0.40; 95% confidence interval [CI]: 0.22-0.75; p<0.01), among residents in northern (OR, 0.45; 95% CI: 0.37-0.55; p<0.01) and southern (OR, 0.45; 95% CI: 0.35-0.58; p <0.01) Italy than among residents in Central Italy, while the prevalence was significantly higher in participants over 50 years of age than in those under 50 years of age (OR, 1.83; 95% CI: 1.48-2.27; p<0.01). Our findings suggest that sexual intercourse does not have a relevant role in HEV transmission. In particular, sexual transmission of HEV is unlikely to influence the prevalence of HEV infection at population level.

Sections du résumé

BACKGROUND
The routes of hepatitis E virus (HEV) transmission have still not been fully clarified. Here, we evaluated the possibility of sexual transmission of HEV, which remains a highly disputed issue.
MATERIALS AND METHODS
Hepatitis E virus sexual transmission risk was assessed by comparing the prevalence of HEV infection in a sample of 196 Italian men who have sex with men (MSM) involved in a multi-country hepatitis A virus (HAV) outbreak, and in 3,912 Italian male blood donors selected from the same regions and provinces as the MSM. Selection of study of participants was motivated by the fact that HEV prevalence among Italian blood donors has been found to vary enormously between different geographical areas.
RESULTS
Anti-HEV IgG prevalence was 14.8% and 5.6% in blood donors and MSM, respectively. Adjusted anti-HEV IgG prevalence was significantly lower in MSM than in blood donors (odds ratio [OR], 0.40; 95% confidence interval [CI]: 0.22-0.75; p<0.01), among residents in northern (OR, 0.45; 95% CI: 0.37-0.55; p<0.01) and southern (OR, 0.45; 95% CI: 0.35-0.58; p <0.01) Italy than among residents in Central Italy, while the prevalence was significantly higher in participants over 50 years of age than in those under 50 years of age (OR, 1.83; 95% CI: 1.48-2.27; p<0.01).
DISCUSSION
Our findings suggest that sexual intercourse does not have a relevant role in HEV transmission. In particular, sexual transmission of HEV is unlikely to influence the prevalence of HEV infection at population level.

Identifiants

pubmed: 31846607
pii: 2019.0209-19
doi: 10.2450/2019.0209-19
pmc: PMC6917535
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

428-432

Références

Lancet. 1994 Nov 19;344(8934):1433
pubmed: 7968090
J Infect. 2017 Mar;74(3):310-313
pubmed: 27998748
J Viral Hepat. 2018 Jun;25(6):752-758
pubmed: 29377436
Euro Surveill. 2016 Jul 28;21(30):
pubmed: 27494608
PLoS One. 2018 Jan 25;13(1):e0191798
pubmed: 29370254
PLoS One. 2015 Mar 09;10(3):e0119576
pubmed: 25751574
Blood Transfus. 2017 Oct;15(6):502-505
pubmed: 29059041
Clin Infect Dis. 2010 Apr 1;50(7):1006-10
pubmed: 20178415
Euro Surveill. 2018 Aug;23(33):
pubmed: 30131095
Euro Surveill. 2015 May 14;20(19):27-34
pubmed: 25990359
Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):
pubmed: 29530946
Clin Microbiol Rev. 2014 Jan;27(1):116-38
pubmed: 24396139
Hepatology. 2019 Dec;70(6):1892-1902
pubmed: 31100186
HIV Med. 2012 Jan;13(1):83-8
pubmed: 21819531
BMJ Open. 2015 Jul 14;5(7):e007110
pubmed: 26173715
AIDS. 2014 Aug 24;28(13):1931-7
pubmed: 24979724
Emerg Infect Dis. 2013 Feb;19(2):333-5
pubmed: 23460994
Aliment Pharmacol Ther. 2017 Jul;46(2):126-141
pubmed: 28449246
Epidemiol Infect. 2017 Dec;145(16):3370-3374
pubmed: 29103401
J Med Virol. 2018 Aug;90(8):1323-1327
pubmed: 29446470
Viruses. 2016 Aug 06;8(8):
pubmed: 27509518
Emerg Infect Dis. 2011 Jan;17(1):30-7
pubmed: 21192851
J Viral Hepat. 2019 Apr;26(4):506-512
pubmed: 30548124
Euro Surveill. 2017 Apr 20;22(16):null
pubmed: 28449730
Emerg Infect Dis. 2011 Dec;17(12):2309-12
pubmed: 22172156
Hepatology. 2016 Apr;63(4):1145-54
pubmed: 27008201
Blood Transfus. 2018 Sep;16(5):413-421
pubmed: 29757135

Auteurs

Enea Spada (E)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Angela Costantino (A)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Patrizio Pezzotti (P)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Roberto Bruni (R)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Giulio Pisani (G)

National Centre for the Control and Evaluation of Medicines, National Institute of Health, Rome, Italy.

Elisabetta Madonna (E)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Paola Chionne (P)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Matteo Simeoni (M)

National Centre for the Control and Evaluation of Medicines, National Institute of Health, Rome, Italy.

Umbertina Villano (U)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Cinzia Marcantonio (C)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Stefania Taffon (S)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Giuseppe Marano (G)

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Simonetta Pupella (S)

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Giancarlo M Liumbruno (GM)

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Anna R Ciccaglione (AR)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH